

1 **A field evaluation of orally-administered praziquantel against the gill**
2 **fluke *Sparicotyle chrysophrii* infecting gilthead seabream (*Sparus***
3 ***aurata*)**

4

5 Use of PZQ against *S. chrysophrii* in gilthead seabream

6

7

8 Rigos George^{1*}, Glaropoulos Alexis², Tzokas Kostantinos², Gourzioti Evgenia^{3,4},

9 Kogiannou Dimitra¹, Golomazou Eleni⁵

10

11 ¹*Institute of Marine Biology, Biotechnology and Aquaculture, Hellenic Centre for Marine*
12 *Research, 46.7 Athinon - Souniou ave, 19013 Anavyssos, Attiki, Greece*

13 ²*Avramar Aquaculture SA, 19,3 km Markopoulou–Paiania Ave. 19002 Paiania, Greece*

14 ³*Laboratory of Ichthyology and Fish diseases, Faculty of Veterinary Medicine, University of*
15 *Thessaly, 43100 Karditsa, Greece*

16 ⁴*Department of Aquaculture and Fish Diseases, Faculty of Veterinary Science, School of*
17 *Health Sciences, University of Thessaly, Trikalon 224 str., 43100 Karditsa, Greece*

18 ⁵*Department of Ichthyology and Aquatic Environment - Aquaculture Laboratory, School of*
19 *Agricultural Sciences, University of Thessaly, Fytokou str., 38446, Volos, Greece*

20

21

22

23 Correspondence: grigos@hcmr.gr

24 **Acknowledgments**

25 The research was co-funded by Greece and the European Union under the Fisheries
26 and Maritime Operational Program 2014-2020 (75 % EMFF contribution, 25 %
27 National Contribution).

28

29 **Keywords:** Gilthead seabream; *Sparus aurata*; praziquantel; *Sparicotyle chrysophrii*;
30 antiparasitics; efficacy

31

32 **Data Availability Statement**

33 We confirm the absence of shared data.

34

35

36 Introduction

37 Praziquantel (PZQ) is a synthetic broad-spectrum antiparasitic, widely used in
38 veterinary and human medicine (Andrews et al., 1983). As a derivative of
39 pyrazinoisoquinoline, it is highly effective against many species of helminths and
40 cestodes. Although its mechanism of action lacks full understanding, PZQ seems to
41 affect the integumental membrane of the parasite, disrupting the regulatory
42 processes and inducing spastic paralysis (Staudt et al., 1992; Bais, Greenberg, 2018).
43 Following a recent opinion of the Committee for Veterinary Medicinal Products
44 (CVMP), PZQ was included in the group of 'allowed substances' (Annex to Commission
45 Regulation No 37/2010), with a proposed maximum residue level (MRL) of 20 µg/kg in
46 finfish muscle plus skin (EMA, 2022). PZQ however, has a long use in the Norwegian
47 salmon farming industry against *Eubothrium* sp. infections (Lunestad et al., 2015)
48 under specific veterinary prescription, and has been applied with success as aquatic
49 medicine in several Asian countries (ASEAN, 2013) and in Australia.

50 There is a vast amount of literature on the control of fish platyhelminths by PZQ
51 administered either by bath or via the feed (Bader et al., 2019). The drug has been
52 tested against numerous fish parasites by applying various dietary treatment
53 schedules with doses ranging from 5 to even 800 mg/kg/day. PZQ has shown
54 remarkable efficacy as a fish anthelmintic in most cases (Bader et al., 2019; Norbury
55 et al., 2022). These promising findings have triggered preliminary field attempts to
56 combat helminths of Mediterranean-farmed fish with PZQ administered through the
57 feed. In particular, PZQ administered at 150 mg/kg for three days showed ~80%
58 reduction of the monogenean *Zeuxapta seriolae* in greater amberjack (*Seriola*
59 *dumerili*) (Rigos et al., 2021).

60 The gill fluke *Sparicotyle chrysophrii* is undoubtedly the most severe pathogen of
61 farmed gilthead seabream (Muniesa et al., 2020), causing considerable losses,
62 reduced feed utilization, and growth retardation, predominantly at high (>20°C) water
63 temperatures (Sitjà-Bobadilla et al., 2009a). The parasite feeds on host tissue cells and
64 blood, causing irritation, gill hyperplasia, overproduction of mucus and hemorrhages,
65 and respiratory and osmoregulatory dysfunctions, leading to severe anaemic
66 conditions and eventually to death (Sitjà-Bobadilla, Alvarez-Pellitero, 2009b; Henry et
67 al., 2015).

68 Treatment of sparicotylosis in caged gilthead seabream is mainly based on formalin
69 (37-40% formaldehyde) baths, the most commonly applied ectoparasitic measure in
70 fish therapy (Boyd, McNevin, 2015). Although formalin is an effective anthelmintic
71 solution, bath application in large pens is laborious, costly, weather dependent, and
72 occasionally infeasible in open sea conditions. Formaldehyde can be also toxic to fish
73 if improperly applied, while formalin baths are restricted in several European
74 countries. Consequently, an effective dietary medicine such as PZQ would be an ideal
75 solution to overcome the drawbacks associated with formalin applications in large
76 cages. For this reason, this work aimed to evaluate the efficacy of PZQ against *S.*
77 *chrysophrii* infections in caged gilthead seabream.

78

79 **Materials and methods**

80

81 **Facilities and fish**

82 The efficacy trial was carried out at a cage farming unit owned by Avramar in the
83 Ionian Sea, Greece. A set-up of six small net cages (3m³ total volume/ 2 m³ clear net
84 volume in water; 1x1x3m) was arranged in a floating collar to accommodate fish
85 receiving or not PZQ feed treatment in triplicate. During the trial, the seawater
86 temperature ranged at 23 ± 1°C, salinity was 38 ppt, and oxygen saturation at
87 approximately 80%.

88 *S. chrysophrii*-infected gilthead seabreams (62.7 ± 16.6 g) were obtained from an
89 adjacent cage. When the number of parasites in the four outer gill arches (two from
90 each side) of the fish reached approximately 8 parasites (adults and juveniles), 780
91 fish were transferred from the donor cage and randomly divided in each of the six
92 experimental cages (4 kg/m³). According to regular monitoring, this is a parasitic load
93 capable of causing progression of the disease in caged gilthead seabream. The
94 mortality was daily recorded during the experimentation.

95

96 **Experimental diets, PZQ dosing, and feeding management**

97 The experimental diets were produced in the facilities of the Hellenic Centre for
98 Marine Research in Anavyssos, Attika). PZQ (50%) was supplied by Vethellas S.A. The
99 formulation of the two experimental diets used for the PZQ trial (control vs 150 mg
100 PZQ/kg fish) is provided in Table 1. Two pelleted feeds were coated externally with
101 the drug and 3% fish oil as a feed attractant to mask the taste of PZQ. Krill meal was
102 incorporated as a feed component into the diet formulation to also induce an
103 additional masking effect (Oikawa, March, 1997; Querol et al., 2012). During the

104 experimentation, fish were fed by hand at two time -points at a daily feeding rate of
105 2%. The duration of each meal was 20-30 min. Fish served as control received the
106 experimental diet without PZQ, while treated fish were given a diet including 150 mg
107 PZQ/kg/day, for three consecutive days only in the first meal (1%) of the day, while
108 the remaining necessary daily feed quantity was completed by the control feed.
109 Feeding was carefully monitored to ensure complete diet consumption.

110

111 **Counting of parasitic load**

112 To assess parasitic prevalence and intensity, ten fish were sampled from each of the
113 six experimental cages. Sampling was carried out 24 hours before the first and after
114 the last medication. Sampled fish were killed using ice-slurry immersion and their four
115 outer gill arches were excised, placed in petri dishes with a few drops of filtered
116 seawater, and examined under a stereoscope for parasitic counting (adults and
117 juveniles). The aforementioned methodology has been previously considered a valid
118 and representative process of parasitic counting (Rigos et al., 2016).

119

120 **Statistical examination**

121 The non-parametric χ^2 test was applied to find statistical differences in parasitic load
122 between untreated and PZQ-treated groups. The level of significance was set at 95%.
123 The efficacy (%) of PZQ against *S. chrysophrii* in gilthead seabream or percentage
124 reduction in mean *S. chrysophrii*, relative to the control group was assessed as
125 previously suggested for parasites (Stone et al., 2000a,b), while mean prevalence,

126 mean abundance, and mean intensity were calculated according to Bush et al. (1997),
127 as follows:

128 % Efficacy= $100 - [100 * (\text{mean number of parasites in PZQ-treated group}) / (\text{mean}$
129 $\text{number of parasites in the control group})]$

130 Mean prevalence= $(\text{number of hosts infected with parasites} / \text{total number of fish}$
131 $\text{examined})$

132 Mean abundance= $(\text{total number of parasites} / \text{total number of fish examined})$

133 Mean intensity= $(\text{total number of parasites} / \text{total number of hosts infected with}$
134 $\text{parasites})$.

135 **Ethical statement**

136 Procedures involving fish were performed according to the EU guidelines on the
137 protection of animals used for scientific purposes (Directive 2010/63/EU). Avramar's
138 facility is certified (Vet code: GR01FISH0004) and licensed for the rearing and use of
139 fish for scientific purposes (EL 01 BIO exp 02). The experimental protocol was
140 approved by the Ethics Committee of the competent authority (275108/1189/21-10-
141 2020). Despite not being in full accordance with Directive 2010/63/EU, sampled fish
142 were killed using ice-slurry immersion, a practice commonly accepted for
143 Mediterranean fish species (Council Regulation No 1099/2009; Commission Report
144 COM/2018/087 final). This aimed to avoid complications in the accurate measurement
145 of gill monogeneans caused by immediate parasitic dislocation due to the use of
146 anesthetics.

147

148 **Results & Discussion**

149 Although the efficacy of dietary PZQ has been sporadically evaluated in unpublished
150 preliminary field attempts against fish helminths of Mediterranean farmed finfish
151 species, the present study describes the first organized trial to assess the
152 anthelmintic effects of the drug against *S. chrysophrii* in gilthead seabream.

153 The estimated prevalence, mean abundance, and mean intensity of *S. chrysophrii* in
154 the sampled fish are provided in Table 2. Reduction of mean intensity in the PZQ-
155 treated group was significant ($P<0.05$) when a comparison was carried out between
156 two experimental groups of fish (2.6 ± 0.5 vs 8.0 ± 1.3), or between the same group
157 before and after treatment. No mortalities were observed during the efficacy trial.

158 Reduced efficacy of PZQ may be attributed to its bitter taste, causing palatability
159 problems and diminished consumption of the PZQ-medicated diets (Partridge et al.,
160 2014). Reduced intake of PZQ-medicated diets necessitates the inclusion of masking
161 agents (Pilmer, 2016) along with specific feed management to improve feed
162 acceptance. The PZQ-medicated diet administered to gilthead seabream was well
163 accepted herein, as was recently seen in *Z. seriolae*-infected greater amberjack (Rigos
164 et al., 2021). The inclusion of krill meal in the dietary components in addition to the
165 external coating with fish oil acted as effective masking agents in the medicated diets
166 used. Perhaps, the dose of PZQ used in the present study approaches the palatability
167 burden in this species since former laboratory attempts to feed PZQ to gilthead
168 seabream at doses of 200-400 mg/kg for the treatment of *S. chrysophrii*, revealed that
169 the effective dose ingested by the fish could not exceed 158 mg/kg for six days (Sitjà-
170 Bobadilla et al., 2006).

171 The high (86%) anthelmintic efficacy of the PZQ treatment found in this study,
172 combined with the significant decrease in the mean parasitic intensity between
173 treated and control fish, meets the suggested criteria proposed by Somerville et al.
174 (2016). A similarly high PZQ efficacy has also been observed using also 150 mg/kg for
175 three days against *Z. seriolae* in greater amberjack (80.4%). The high anthelmintic
176 efficacy of PZQ seen in these two studies and elsewhere (Williams et al., 2007;
177 Yamamoto et al., 2011; Forwood et al., 2016), may be connected to its high
178 bioavailability values in farmed fish. Indeed, the absorption of PZQ seems to be
179 promising in gilthead seabream (Kogiannou et al, 2023) and yellowtail amberjack (*S.*
180 *lalandi*) (Tubbs, Tingle, 2006a), reaching values as high as 50%, exceeding those
181 estimated for terrestrial animals (3 to 32%) (Zeng et al., 1993; Cao et al., 2001; Giorgi
182 et al., 2001), perhaps due to considerable first-pass effect on absorbed PZQ on
183 livestock (Andrews et al., 1983).

184 Therapeutic strategies against flukes in aquaculture medicine necessitate consecutive
185 anthelmintic treatments, considering the incubation period of the parasitic eggs and
186 the survival of the infective swimming larvae (Villar-Torres et al., 2018). Based on the
187 current field knowledge and the pertinent literature (Villar-Torres et al., 2018; 2023),
188 three to four monthly treatments against *S. chrysophrii* are approximately advised
189 during the warm periods. Improved cage hygiene accomplished by several means (e.g.
190 ROVs), and frequent net replacement, may affect the viability of parasitic eggs and
191 thus, reduce the frequency of anthelmintic therapy. Another challenge when battling
192 monogeneans in aquatic medicine is the necessity to prevent reinfection at the farm
193 level which seems a considerable problem in Mediterranean aquaculture where farms
194 have several fish generations together. This causes a perpetual reinfection of

195 pathological agents and it is the main risk factor, not only for parasites, but for
196 infectious diseases in general. This issue would require simultaneous therapy of all fish
197 stocks maintained on the farm, which is virtually impossible, especially with chemical
198 baths. Fortunately, the availability of dietary antiparasitics with evidenced
199 anthelmintic efficacy as PZQ would allow simultaneous treatment of all the
200 susceptible fish sizes in an infected population.

201 In conclusion, the findings of the present study indicate that oral PZQ treatments using
202 specific feeding management can considerably control *S. chrysophrii* infections in
203 farmed gilthead seabream. Dietary PZQ administration should also be assessed
204 against other important helminths of Mediterranean finfish farmed species such as
205 *Cardicola* spp. infections (Palacios-Abella et al., 2021), that may co-infect gilthead
206 seabream.

207

208

209

210

211

212

213

214

215

216 References

- 217 Andrews, P., Thomas, H., Pohlke, R., Seubert, J., 1983. Praziquantel. Medicinal Research
218 Reviews. 3, 147-200.
- 219 ASEAN, 2013. Association of Southeast Asian Nations, Guidelines for the Use of Chemicals in
220 Aquaculture and Measures to Eliminate the Use of Harmful Chemicals. Jakarta,
221 ASEAN Secretariat.
- 222 Bader, C., Starling, D.E., Jones, D.E., Brewer, M.T., 2019. Use of praziquantel to control
223 platyhelminth parasites of fish. Journal of Veterinary Pharmacology and
224 Therapeutics. 42, 139-153.
- 225 Bais, S, Greenberg, R.M., 2018. TRP channels as potential targets for antischistosomes. Int J
226 Parasitol Drugs. Drug Resistance. 8, 511-517.
- 227 Boyd, C.E., McNevin, A.A., 2015. Chemicals in Aquaculture, Aquaculture, Resource Use, and
228 the Environment, pp. 173-210.
- 229 Bush, A.O., Lafferty, K.D., Lotz, J.M., Shostak, A.W., 1997. Parasitology Meets Ecology on Its
230 Own Terms: Margolis et al. Revisited. The Journal of Parasitology. 83, 575-583.
- 231 Cao, J., Liu, E., Zhao, J., Li, K., Dou, S., 2001. Pharmacokinetics and bioavailability of
232 praziquantel in cattle after oral, intramuscular and intravenous administration. Chin J
233 Vet Sci. 21, 612-614.
- 234 EMA, 2022. European Medicine Agency, Committee for Medicinal Products for Veterinary
235 Use (9 September 2022). Praziquantel MRL summary opinion.
236 EMA/CVMP/706481/2022.
- 237 Forwood, J.M., Bubner, E.J., Landos, M., Deveney, M.R., D'Antignana, T., 2016. Praziquantel
238 delivery via moist pellets to treat monogenean parasites of yellowtail kingfish *Seriola*
239 *lalandi*: efficacy and feed acceptance. Diseases of Aquatic Organisms. 121, 201-209.
- 240 Giorgi, M., Salvatori, A.P., Soldani, G., Giusiani, M., Longo, V., Gervasi, P.G., Mengozzi, G.,
241 2001. Pharmacokinetics and microsomal oxidation of praziquantel and its effects on
242 the P450 system in three-month-old lambs infested by *Fasciola hepatica*. Journal of
243 Veterinary Pharmacology and Therapeutics. 24, 251-259.
- 244 Henry, M.A., Nikoloudaki, C., Tsigenopoulos, C., Rigos, G., 2015. Strong effect of long-term
245 *Sparicotyle chrysophrii* infection on the cellular and innate immune responses of
246 gilthead sea bream, *Sparus aurata*. Dev Comp Immunol. 51, 185-193.
- 247 Kogiannou, D., Nikoloudaki, C., Valsamidi, V., Kotsiri, M., Golomazou, E., Rigos, G., 2023.
248 Pharmacokinetics of praziquantel in gilthead seabream (*Sparus aurata*) plasma and
249 gills, Aquaculture, 739975.
- 250 Lunestad, B., Hannisdal, R., Samuelsen, O., 2015. Safety of medical feed additives in the food
251 chain. in: DA, D. (Ed.), Feed and Feeding Practices in Aquaculture. Woodhead
252 Publishing, Oxford, pp. 251–268.
- 253 Muniesa, A., Basurco, B., Aguilera, C., Furones, D., Reverté, C., Sanjuan-Vilaplana, A., Jansen,
254 M.D., Brun, E., Tavoranpanich, S., 2020. Mapping the knowledge of the main diseases
255 affecting sea bass and sea bream in Mediterranean. Transboundary and Emerging
256 Diseases. 67, 1089-1100.
- 257 Norbury, L.J., Shirakashi, S., Power, C., Nowak, B.F., Bott, N.J., 2022. Praziquantel use in
258 aquaculture - Current status and emerging issues. International Journal for
259 Parasitology. Drugs and drug resistance. 18, 87-102.
- 260 Oikawa, C.K., March, B.E., 1997. Communications: A method for assessment of the efficacy
261 of feed attractants for fish. Progressive Fish-Culturist. 59, 213-217.
- 262 Palacios-Abella, J., Montero, F., Merella, P., Mele, S., Raga, J., Repullés-Albelda, A., 2021.
263 *Cardicola mediterraneus* n. sp. (Trematoda, Aporocotylidae): a new species infecting
264 the gilthead seabream, *Sparus aurata* L., from the Western Mediterranean Sea.
265 Parasitology Research. 120, 1-15.

266 Partridge, G., Michael, R., Thuillier, L., 2014. Praziquantel form, dietary application method
267 and dietary inclusion level affect palatability and efficacy against monogenean
268 parasites in yellowtail kingfish. *Diseases of Aquatic Organisms*. 109, 155-163.

269 Pilmer, L., 2016. Novel methods of improving the palatability of feeds containing
270 praziquantel for commercially cultured yellowtail kingfish, Honours thesis. Murdoch
271 University.

272 Querol, P., Morillo-Velarde, P., Cerezo Valverde, J., Martínez-Llorens, S., Moñino, Jover,
273 Tomás-Vidal, A., 2012. Inclusion of fish and krill meal in extruded diets for *Octopus*
274 *vulgaris* (Cuvier, 1797): Assessment of acceptance. *Aquaculture Research*. 45.

275 Rigos, G., Kogiannou, D., Vasilaki, A., Kotsiri, M., 2021. Evaluation of Praziquantel Efficacy
276 against *Zeuxapta seriolae* Infections in Greater Amberjack, *Seriola dumerili*. *Applied*
277 *Sciences*. 11, 4656.

278 Rigos, G., Mladineo, I., Nikoloudaki, C., Vrbatovic, A., Kogiannou, D., 2016. Application of
279 compound mixture of caprylic acid, iron and mannan oligosaccharide against
280 *Sparicotyle chrysophrii* (Monogenea: Polyopisthocotylea) in gilthead sea bream,
281 *Sparus aurata*. *Folia Parasitol (Praha)*. 63.

282 Sitjà-Bobadilla, A., Alvarez-Pellitero, P., 2009b. Experimental transmission of *Sparicotyle*
283 *chrysophrii* (Monogenea: Polyopisthocotylea) to gilthead seabream (*Sparus aurata*)
284 and histopathology of the infection. *Folia Parasitologica*. 56, 143-151.

285 Sitjà-Bobadilla, A., de Felipe, M.C., Alvarez-Pellitero, P., 2006. In vivo and in vitro treatments
286 against *Sparicotyle chrysophrii* (Monogenea: Microcotylidae) parasitizing the gills of
287 gilthead sea bream (*Sparus aurata* L.). *Aquaculture*. 261, 856-864.

288 Sitjà-Bobadilla, A., Redondo, M., Alvarez-Pellitero, P., 2009a. Occurrence of *Sparicotyle*
289 *chrysophrii* (Monogenea: Polyopisthocotylea) in gilthead sea bream (*Sparus aurata*
290 L.) from different mariculture systems in Spain. *Aquaculture Research - AQUAC RES*.
291 41, 939-944.

292 Sommerville, C., Endris, R., Bell, T.A., Ogawa, K., Buchmann, K., Sweeney, D., 2016. World
293 association for the advancement of veterinary parasitology (WAAVP) guideline for
294 testing the efficacy of ectoparasiticides for fish. *Veterinary Parasitology*. 219, 84-99.

295 Staudt, U., Schmahl, G., Blaschke, G., Mehlhorn, H., 1992. Light and scanning electron
296 microscopy studies on the effects of the enantiomers of praziquantel and its main
297 metabolite on *Schistosoma mansoni* in vitro. *Parasitology Research*. 78, 392-397.

298 Stone, J., Sutherland, I.H., Sommerville, C., Richards, R.H., Varma, K.J., 2000a. Field trials to
299 evaluate the efficacy of emamectin benzoate in the control of sea lice,
300 *Lepeophtheirus salmonis* (Kroyer) and *Caligus elongatus* Nordmann, infestations in
301 Atlantic salmon *Salmo salar* L. *Aquaculture*. 186, 205-219.

302 Stone, J., Sutherland, I.H., Sommerville, C., Richards, R.H., Varma, K.J., 2000b. Commercial
303 trials using emamectin benzoate to control sea lice *Lepeophtheirus salmonis*
304 infestations in Atlantic salmon *Salmo salar*. *Diseases of Aquatic Organisms* . 41, 141-
305 149.

306 Tubbs, L.A., Tingle, M.D., 2006a. Bioavailability and pharmacokinetics of a praziquantel bolus
307 in kingfish *Seriola lalandi*. *Diseases of Aquatic Organisms*. 69, 233-238.

308 Villar-Torres, M., Montero, F.E., Raga, J.A., Repullés-Albelda, A., 2018. Come rain or come
309 shine: environmental effects on the infective stages of *Sparicotyle chrysophrii*, a key
310 pathogen in Mediterranean aquaculture. *Parasites & Vectors*. 11, 558.

311 Villar-Torres, M., Montero, F.E., Raga, J.A., Repullés-Albelda, A., 2023. The influence of water
312 temperature on the life-cycle of *Sparicotyle chrysophrii* (Monogenea:
313 Microcotylidae), a common parasite in gilthead seabream aquaculture. *Aquaculture*.
314 565, 739103.

315 Williams, R., Ernst, I., Chambers, C., Whittington, I., 2007. Efficacy of orally administered
316 praziquantel against *Zeuxapta seriolae* and *Benedenia seriolae* (Monogenea) in
317 yellowtail kingfish *Seriola lalandi*. *Diseases of Aquatic Organisms*. 77, 199-205.
318 Yamamoto, S., Shirakashi, S., Morimoto, S., Ishimaru, K., Murata, O., 2011. Efficacy of oral
319 praziquantel treatment against the skin fluke infection of cultured chub mackerel,
320 *Scomber japonicus*. *Aquaculture*. 319, 53-57.
321 Zeng, Z., Chen, Z., Feng, Q., 1993. Pharmacokinetics and oral bioavailability of praziquantel in
322 pigs following a single dose. *Chin J Anim Vet Sci* 24, 170-174.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350 **Table 1.** Formulation and composition of experimental diets (3mm pellets) for the
 351 PZQ trial

Basic dietary components		
	Control (%)	PZQ-treated (%)
Fish meal	24.0	24.0
Krill meal	5.0	5.0
Poultry meal	13.0	13.0
Soy protein concentrate	4.4	4.4
Corn gluten	16.5	16.5
Soybean meal	10.0	10.0
Rapeseed meal	5.0	5.0
Wheat Flour	10.2	7.2
Fish oil	4.4	4.4
Salmon oil	6.0	6.0
Monocalcium phosphate	0.3	0.3
Phospholipid source	0.2	0.2
Premix of vitamins and minerals	1.0	1.0
Top coating components		
Fish oil	3.0	3.0
Praziquantel 50% (Vethellas)	-	3.0
Proximate composition		g/100g
Crude protein		48
Total carbohydrates		20
Crude lipids		15
Moisture		8

Total ash	7
Crude fiber	2

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367 **Table 2.** Prevalence, mean abundance and mean intensity of *S. chrysophrii* in gilthead
 368 seabream before and after PZQ treatment (dosed with 150 mg/kg for three days).
 369 Different letters (a, b) denote significant differences between groups (P<0.05). Data
 370 are presented as means \pm st.dev.

	PZQ-treated	Control
<i>Prior to treatment</i>		
Prevalence (%)	100 \pm 0.0	96.3 \pm 6.4
Mean abundance	8.2 \pm 0.7	6.7 \pm 1.3
Mean intensity	8.2 \pm 0.7	7.0 \pm 1.0
<i>After treatment</i>		
Prevalence (%)	56.7 \pm 28.9	100 \pm 0.0
Mean abundance	1.5 \pm 0.9 ^a	8.0 \pm 1.3 ^b
Mean intensity	2.6 \pm 0.5 ^a	8.0 \pm 1.3 ^b

371